Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Alnylam Pharmace. buy The Goldman Sachs Group, Inc.

Alnylam Pharmace.
Start price
€240.00
16.08.24 / 50%
Target price
€336.33
16.08.25
Performance (%)
58.83%
End price
€381.20
17.08.25
Summary
This prediction ended on 17.08.25 with a price of €381.20. With a performance of 58.83% the BUY prediction by The_Goldman_Sachs_Gr was a big success. The_Goldman_Sachs_Gr has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. The_Goldman_Sachs_Gr has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Performance without dividends (%)
Name 1w 1m 1y
Alnylam Pharmace. -0.766% -0.766% 58.282%
iShares Core DAX® -0.560% -3.108% 25.227%
iShares Nasdaq 100 1.622% 4.701% 18.666%
iShares Nikkei 225® 1.807% 5.094% 10.642%
iShares S&P 500 0.859% 2.906% 12.205%

Comments by The_Goldman_Sachs_Gr for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) 58.83%
Target price 336.330
Change
Ends at 16.08.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $370.00 price target on the stock, up previously from $198.00.
Ratings data for ALNY provided by MarketBeat

The Goldman Sachs Group, Inc. 
0
Report Share
16.08.24
In the thread Trading Alnylam Pharmace.
Prediction Buy
Perf. (%) 58.83%
Target price 336.330
Change
Ends at 16.08.25

Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten

The Goldman Sachs Group, Inc. 
0
Report Share
17.08.25

Current prediction by The_Goldman_Sachs_Gr for Alnylam Pharmace.

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€388.70
16.09.25
€480.99
16.09.26
0.05%
22.09.25

The Goldman Sachs Group, Inc. 
16.09.25 50%